Incendia enrols first subject in Phase Ic advanced solid tumour trial
Incendia Therapeutics has enrolled the first subject in a Phase Ic trial of PRTH-101, a DDR1 inhibitor for advanced solid tumours. The open-label trial will assess PRTH-101's safety, tolerability, and anti-tumour activity, both alone and with pembrolizumab. Up to 270 patients will be enrolled in the US, with the study aiming to determine optimal dosing for future Phase II programmes and explore DDR1 as a biomarker for patient responses.
Reference News
Incendia Therapeutics has enrolled the first subject in a Phase Ic trial of PRTH-101, a DDR1 inhibitor for advanced solid tumours. The open-label trial will assess PRTH-101's safety, tolerability, and anti-tumour activity, both alone and with pembrolizumab. Up to 270 patients will be enrolled in the US, with the study aiming to determine optimal dosing for future Phase II programmes and explore DDR1 as a biomarker for patient responses.